Trials / Conditions / BRCA1-Associated Protein-1 (BAP1) Mutations

BRCA1-Associated Protein-1 (BAP1) Mutations

3 registered clinical trials studyying BRCA1-Associated Protein-1 (BAP1) Mutations — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Withdrawn	Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma NCT06654050	National Cancer Institute (NCI)	Phase 2
Suspended	Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition NCT05960773	National Cancer Institute (NCI)	Phase 2
Recruiting	Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biops NCT04431024	National Cancer Institute (NCI)	—